Pomerantz Law Firm Investigates Johnson & Johnson Following Q3 2026 Earnings Miss
Pomerantz LLP has launched an investigation into Johnson & Johnson (JNJ) regarding potential securities fraud or unlawful business practices. The probe follows the company's third-quarter 2026 financial report, which revealed a significant drop in GAAP net earnings to just $210 million ($0.09 per share). This decline was primarily driven by multi-billion dollar special charges related to ongoing talc litigation settlements. Additionally, J&J's MedTech segment reported a revenue miss, growing only 2.5% to $8.64 billion. The company cited international pricing constraints in China and geopolitical disruptions in the Middle East as key headwinds. Following these disclosures on October 13, 2026, JNJ shares fell by 5.73%, closing at $248.61 per share.
Tickers: $JNJ
Topics: class action lawsuit earnings miss MedTech revenue decline securities fraud investigation talc litigation
Read the full article at PR Newswire
Part of the story Reddit Shares Plunge 29% Following Weak Earnings and Declining Search Traffic (31 articles)